Clinical trials
Locally Advanced (Unresectable) or Metastatic Solid Tumors clinical trials
Below are recruiting locally advanced (unresectable) or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 2,077 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05727787Recruiting
Radiation trial for liver cancer that cannot be removed
This Phase I study tests a specific radiation approach (vGRID SBRT) for hepatocellular carcinoma (and some mixed types) that is advanced and cannot be cured with surgery or transplant. It aims to control tumors while staying within safety limits for the liver and nearby organs.
Kansas City, KansasAges 18 years+ - NCT05655312RecruitingPhase 1/Phase 2
Targeted radiation melanoma treatment with or without nivolumab
This early-stage study tests whether a targeted radioactive drug can shrink advanced melanoma, either alone or along with nivolumab (an immune-activating medicine). You may be eligible if your melanoma shows a specific target on scan imaging and has progressed despite prior melanoma treatments.
Orange, CaliforniaAges 18–90 - NCT05525767RecruitingPhase 4
Bevacizumab plus chemo before surgery for HER2-negative breast cancer
This trial studies whether adding bevacizumab (an anti-blood-vessel medicine) to chemotherapy before surgery improves treatment outcomes for people with HER2-negative breast cancer. It’s mainly for tumors that are stage II to IIIC and have not had prior cancer treatment.
Shijiazhuang, HebeiAges 18 years+ - NCT05503797RecruitingPhase 2
Study of FORE8394 for cancers with BRAF changes
This trial tests a new drug, FORE8394, for people whose cancers have a change in the BRAF gene. It may be an option if you have a solid tumor or brain tumor that has not responded to other treatments.
Beverly Hills, CaliforniaAges 8 years+ - NCT05443087Recruiting
Checking blood levels of targeted drugs for digestive cancers
This trial monitors how your prescribed targeted cancer medicine moves through your body by doing extra blood tests. The goal is to understand the drug’s levels and dosing in people with advanced digestive cancers, so treatment can be better managed.
AmiensAges 18 years+ - NCT05317819RecruitingPhase 3
Test ADI-PEG 20 versus placebo for advanced liver cancer
This study tests whether ADI-PEG 20 helps people with advanced, unresectable hepatocellular carcinoma (liver cancer) who have high arginine levels. Participants get ADI-PEG 20 or a placebo to see which works better and improves outcomes.
ChanghuaAges 18–99 - NCT05390827Recruiting
Remote health tracking for people with and without cancer
This study uses a smartphone app to collect health data like activity and heart rate over several months, to help understand how cancer and treatment affect patients. It may help improve care for people with cancer and those at risk.
New York, New YorkAges 18 years+ - NCT05371132RecruitingPhase 1
PET scan study to track immune response after SBRT
This early (Phase 1) study uses a special PET scan to measure how your immune system responds after stereotactic body radiation therapy (SBRT). The goal is to see whether the scan result can serve as a marker of immune response, which may help future treatment planning.
Duarte, CaliforniaAges 18 years+ - NCT05223608Recruiting
Study of people starting immunotherapy for solid tumors
This study follows people who are starting their first immune “checkpoint” treatment for a solid cancer. It collects clinic information and lab results to understand how patients respond and what factors matter most.
Lille, Hauts-de-FranceAges 18 years+ - NCT05191940Recruiting
Radiation for advanced pancreatic cancer you can’t remove by surgery
This trial studies how well radiation therapy works for pancreatic cancer that is locally advanced (near important blood vessels) and cannot be removed with surgery. It may help shrink or control the cancer when surgery isn’t an option.
Wiener Neustadt, Lower AustriaAges 18 years+ - NCT05125016RecruitingPhase 1/Phase 2
Study drug for advanced prostate cancer after standard treatments
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
Palo Alto, CaliforniaAges 18 years+ - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT04764357Recruiting
Scalp cooling to help prevent chemotherapy-related hair loss in kids
This study looks at whether “cold cap” scalp cooling can help prevent or reduce hair loss in children getting chemotherapy. It’s aimed at kids treated with certain chemotherapy medicines and who may be at risk for losing their hair.
Memphis, TennesseeAges 7 years+ - NCT04762862Enrolling by invitation
Testing gene-guided cancer treatment changes in advanced tumors
This trial studies whether measuring changes in your tumor’s genes (from pangenomic quantitative testing) can help guide cancer treatment when standard cures aren’t available. It may help doctors choose therapies based on what your tumor shows.
NiceAges Any age - NCT04613596RecruitingPhase 2/Phase 3
Adagrasib for KRAS G12C lung cancer, alone or with pembrolizumab
This trial studies adagrasib (an anti-cancer drug) either alone or with pembrolizumab (an immunotherapy) in people with advanced lung cancer that has a KRAS G12C mutation. It aims to shrink tumors and improve outcomes, including for people without urgent brain treatment needs.
Goodyear, ArizonaAges 18 years+ - NCT04665388Recruiting
Mapping immune responses in people with certain virus-related cancers
This study collects blood and/or tumor-related samples to map how your immune system recognizes cancer. It aims to better understand immune targets and immune cell types, which may help guide future cancer treatments for certain virus-related cancers.
Toronto, OntarioAges 18 years+ - NCT03977233RecruitingPhase 2
Biopsies and FOLFIRINOX for non-metastatic pancreatic cancer
This Phase 2 study looks at different types (subtypes) of pancreatic tumors in people treated with FOLFIRINOX, a chemotherapy. It requires tumor biopsies before and after treatment to see how the tumor changes, which may help doctors better match treatments in the future.
Chapel Hill, North CarolinaAges 18–99 - NCT04516447RecruitingPhase 1
Testing a new drug for advanced ovarian cancer
This Phase 1 trial studies how well and how safely azenosertib (ZN-c3) works in people with advanced ovarian, fallopian tube, or peritoneal cancer. It may help by offering a new treatment option for cancers that don’t respond well to platinum chemotherapy (platinum-resistant).
Aurora, ColoradoAges 18 years+ - NCT04205968RecruitingPhase 2
Testing ramucirumab with chemo for advanced small bowel cancer
This trial studies whether adding ramucirumab to chemotherapy (either paclitaxel or FOLFIRI) works better for advanced small bowel adenocarcinoma that has already been treated with certain prior medicines. It may help shrink tumors or slow cancer growth in people whose cancer has progressed.
Anchorage, AlaskaAges 18 years+ - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune disease
This trial tests whether the immunotherapy drug nivolumab can safely treat advanced cancer in people who also have an autoimmune disease like rheumatoid arthritis, lupus, or multiple sclerosis. It aims to find out if the drug may help control cancer while managing their autoimmune condition.
Birmingham, AlabamaAges 18 years+ - NCT02421380Recruiting
Tests how repeatable a special MRI scan is for tumors
This study checks whether a specialized MRI using injected “hyperpolarized pyruvate” gives consistent tumor images when repeated. It may help future patients by improving how reliably this scan can measure tumors.
Montvale, New JerseyAges 21–90 - NCT01915225Recruiting
Collecting solid tumor samples during cancer biopsy or surgery
This trial collects tissue (samples) from people who are already scheduled for biopsy or surgery for certain solid cancers. It aims to improve future testing and research while checking that taking the sample is safe and doesn’t add extra risk.
Bethesda, MarylandAges 2 years+ - NCT06472388RecruitingPhase 2
Testing two doses of everolimus for neuroendocrine tumors
This trial compares two daily doses (5 mg vs 10 mg) of everolimus, a targeted therapy, to see which works better and is safer for people with advanced neuroendocrine tumors (NETs). You may qualify if your cancer has grown despite previous treatment and you are in relatively good health.
São Paulo, São PauloAges 16 years+ - NCT07156227RecruitingPhase 1
Testing camonsertib with radiation for returning head and neck cancer
This study tests whether adding the drug camonsertib to radiation therapy can help people whose head and neck cancer has come back in a spot that was already treated with radiation. Camonsertib is an experimental drug that may help radiation work better.
Duarte, CaliforniaAges 18 years+
Hear when a new Locally Advanced (Unresectable) or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced (unresectable) or metastatic solid tumors?
- Yes. Clin2 currently lists 2,077 recruiting locally advanced (unresectable) or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced (unresectable) or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced (unresectable) or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Solid Tumor
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.